TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB

TD Private Client Wealth LLC decreased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 21.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,308 shares of the company’s stock after selling 1,759 shares during the quarter. TD Private Client Wealth LLC’s holdings in Genmab A/S were worth $130,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in GMAB. Mackenzie Financial Corp purchased a new stake in Genmab A/S during the fourth quarter valued at about $689,000. Versant Capital Management Inc grew its position in Genmab A/S by 1,108.3% during the first quarter. Versant Capital Management Inc now owns 8,724 shares of the company’s stock valued at $171,000 after acquiring an additional 8,002 shares during the last quarter. GAMMA Investing LLC grew its position in Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock valued at $656,000 after acquiring an additional 31,343 shares during the last quarter. Park Avenue Securities LLC bought a new position in shares of Genmab A/S in the first quarter worth approximately $276,000. Finally, Fifth Third Bancorp grew its holdings in shares of Genmab A/S by 16.6% in the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company’s stock worth $825,000 after purchasing an additional 6,015 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

GMAB has been the topic of several recent analyst reports. HC Wainwright lifted their price target on shares of Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a report on Friday, August 15th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Tuesday, September 23rd. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Truist Financial lifted their price objective on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. Finally, Wall Street Zen upgraded Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $29.33 on Tuesday. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $29.51. The company has a 50-day moving average of $25.11 and a 200 day moving average of $22.13. The firm has a market cap of $18.82 billion, a PE ratio of 14.74, a price-to-earnings-growth ratio of 1.70 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.